Category: JCN Newswire

KAWASAKI, Japan, Mar 30, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu today announced the launch of Fujitsu Application Transform powered by Fujitsu Kozuchi, a generative AI service that analyzes source code and automatically generates design documents, contributing to a reduction in work time of approximately 97%. Fujitsu will begin offering Fujitsu Application Transform powered by Fujitsu Kozuchi as a SaaS in Japan starting March 30, 2026. This service supports the modernization of companies and organizations by leveraging Fujitsu's extensive system development expertise, proprietary technology, and generative AI to analyze COBOL and other source codes within existing legacy systems, automatically generating design documents to understand the system's content.Building on the achievements of its predecessor, a software analysis and visualization service launched in February 2025, this new offering standardizes analysis technology and design document generation know-how. In this service, Fujitsu proprietary technology leverages code analysis techniques on remaining design information and existing programs and manages RAG using Fujitsu Knowledge Graph–Enhanced RAG for Software Engineering. By linking large volumes of source code, it prevents omissions and hallucinations, and automatically generates highly accurate, easy-to-read design documentation.This service reduces the time-consuming process of understanding programming languages and generating design documents, which previously required extensive human effort, by approximately 97%, even without expert knowledge. Furthermore, compared to analysis solely by general generative AI, Fujitsu's proprietary technology generates consistent design information without omissions from existing system source code, even for complex COBOL language. This has improved comprehensiveness by 95%. These accuracy enhancements have also led to a 60% improvement in the readability of design documents compared to conventional methods, confirming the generation of high-quality design documents.Moving forward, Fujitsu plans to begin offering support services for the introduction of this service. Additionally, beyond automatic design document generation, Fujitsu plans to sequentially introduce features for rebuilding existing source code for future use, automatically rewriting source code, and supporting operation and maintenance, starting in fiscal year 2026. Through this service, Fujitsu aims to generate high-quality design documents, enabling a clear understanding of current system specifications and characteristics, and strongly supporting the formulation and implementation of system modernization and migration strategies.Figure: Fujitsu Application Transform powered by Fujitsu Kozuchi concept diagramToshihiro Horiuchi, Managing Executive Officer, SMBC Nikko Securities Inc. comments:“We see this announcement as an initiative that realistically advances the modernization of our legacy systems by combining Fujitsu’s deep system development expertise built up over many years with generative AI. From fiscal year 2025, we have been conducting joint verification with Fujitsu on reverse-engineering design documentation for legacy languages, including COBOL, and through this collaboration we have come to recognize the significant potential of this technology. Going forward, we hope to continue working closely with Fujitsu to achieve more practical and effective modernization.”Related LinksService Introduction Site(Japanese)Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planningAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Mar 27, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and MSD K.K. (Headquarters: Tokyo, Representative Director: Prashant Nikam, “MSD”), a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, announced today that an application for LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, has been submitted in Japan for the additional dosage and administration in combination with WELIREG® (belzutifan), the first-in-class oral hypoxiainducible factor-2 alpha (HIF-2α) inhibitor from MSD, for the treatment of unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.This application is based on the results of the Phase 3 LITESPARK-011 trial evaluating the dual regimen of LENVIMA plus WELIREG for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. The data from this trial were presented at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium in February 2026. At a pre-specified interim analysis with a median follow-up of 29.0 months (range, 19.3-49.2), the LENVIMA plus WELIREG combination therapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the primary endpoints, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. The safety profile of this combination was consistent with those reported for each agent administered as monotherapy, and no new safety signals were identified.In 2022, approximately 435,000 people worldwide were newly diagnosed with kidney cancer, and about 156,000 people died from the disease. 1 In Japan, it is estimated that roughly 21,000 people were newly diagnosed and about 7,000 died in 2022.2 RCC accounts for approximately 85% of kidney cancers3, and the five-year survival rates for patients with stage III and IV RCC have been reported as 63%–78% and 27%–28%4, respectively, indicating that the disease still has a high unmet medical needs.LENVIMA is approved in combination with KEYTRUDA ® (pembrolizumab) in Japan for the first-line treatment of unresectable or metastatic RCC. WELIREG is approved in Japan for the treatment of unresectable or metastatic RCC that has progressed following cancer chemotherapy. Additionally, supplemental New Drug Applications (sNDA) for the LENVIMA and WELIREG combination therapy for the treatment of adult patients with advanced RCC with a clear cell component following a PD-1 or PDL1 inhibitor has been accepted by the U.S. Food and Drug Administration (FDA), with a PDUFA (Prescription Drug User Fee Act) target action date set for October 4, 2026.Eisai and MSD have been collaborating through the provision of information on LENVIMA in Japan since October 2018, and will work together to expedite the maximization of contribution to patients with cancer.About LENVIMA (lenvatinib)LENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1- 4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization (Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia) The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery.About WELIREG (belzutifan)WELIREG, Merck & Co., Inc., Rahway, NJ, USA’s, known as MSD outside of the United States and Canada, first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival. WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) diseaseassociated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond. WELIREG has been approved in Japan for the treatment of certain von Hippel–Lindau (VHL) disease–associated tumors, as well as for unresectable or metastatic renal cell carcinoma that has progressed after chemotherapy.LITESPARK-011 ResultsData from LITESPARK-011 (ClinicalTrials.gov, NCT04586231) were presented at the ASCO GU Symposium held in February 2026. LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced clear cell RCC that has progressed on or after anti-PD-1/L1 therapy. The dual primary endpoints are progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR), and overall survival (OS). Secondary endpoints include objective response rate (ORR) per RECIST v1.1 as assessed by BICR, duration of response (DOR) per RECIST v1.1 as assessed by BICR, and safety. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily).At a pre-specified second interim analysis with a median follow-up of 29.0 months (range, 19.3- 49.2), WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of PFS, reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. For WELIREG plus LENVIMA, the median PFS was 14.8 months (95% CI, 11.2-16.6) versus 10.7 months (95% CI, 9.2-11.1) for cabozantinib. A trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was also observed for WELIREG plus LENVIMA (HR=0.85 [95% CI, 0.68-1.05]; p=0.06075). The median OS was 34.9 months (95% CI, 27.5-NR) for WELIREG plus LENVIMA versus 27.6 months (95% CI, 24.0-31.4) for cabozantinib. The trial is continuing, and OS will be evaluated at a subsequent analysis per the clinical trial protocol. Regarding secondary endpoints, at the first interim analysis with a median follow-up of 19.6 months (range, 9.9-39.8), WELIREG plus LENVIMA met ORR, demonstrating a statistically significant improvement compared to cabozantinib. A confirmed ORR of 52.6% (95% CI, 47.3-57.7) was observed for WELIREG plus LENVIMA versus 39.6% (95% CI, 34.6-44.8) for cabozantinib. At the second interim analysis with a median follow-up of 29.0 months, the median DOR was 23.0 months (95% CI, 2.0-44.3+) for WELIREG plus LENVIMA versus 12.3 months (95% CI, 1.8+-35.9+) for cabozantinib. WELIREG plus LENVIMA was administered to 370 patients and cabozantinib was administered to 371 patients. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 71.6% of patients receiving WELIREG plus LENVIMA versus 65.8% of patients receiving cabozantinib. Adverse events led to treatment discontinuation in 11.1% of patients receiving WELIREG plus LENVIMA and in 11.3% of patients receiving cabozantinib, respectively. Serious adverse events were observed in 51.6% of patients receiving WELIREG plus LENVIMA versus 43.9% of patients receiving cabozantinib, and AEs led to death in 5.4% of patients (two were treatment-related: thrombotic microangiopathy [n=1] and pneumonitis [n=1]) versus 3.2% (one was treatment-related: hemoptysis [n=1]) of patients, respectively.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “microenvironment”, “protein integrity and homeostasis”, and “cell lineage and cell differentiation” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancers.6. About EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners. For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncologyAbout MSDAt MSD (the name by which Merck & Co., Inc., Rahway, NJ, USA, is known outside of the United States and Canada), we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.co.jp and connect with us on Facebook, Twitter, and YouTube.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf, accessed 27 Mar 2026.Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. (2024) Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, Available from: https://gco.iarc.who.int/media/globocan/factsheets/populations/392-japan-fact-sheet.pdf, accessed 27 Mar 2026.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. 2025; 2026 Version 1. Rose TL and Kim WY. Renal cell carcinoma: a review. JAMA. 2024 Sep 24;332(12):1001– 10.Media InquiriesEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120MSD K.K.Communications DivisionTatsuro MuraseTEL: +81 (0)70-8700-0112 Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

TOKYO, Mar 27, 2026 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501, “Hitachi”) and MUFG Bank, Ltd. (“MUFG Bank”), a consolidated subsidiary of Mitsubishi UFJ Financial Group, Inc. (TYO: 8306, “MUFG”) today announced a new Memorandum of Understanding (MoU) to expand NextGen, their business co-creation model. Building on their collaboration launched in May 2024*1 and further developed as announced in May 2025*2 , NextGen combines Hitachi’s technology and operational expertise with MUFG’s financial capabilities to accelerate the transition to decarbonized mobility.*1 MUFG’s Business Co-Creation and Investment into UK Battery as a Service project by Hitachi ZeroCarbon May 2024*2 Hitachi ZeroCarbon and MUFG unite technology expertise with financial support to accelerate fleet electrification May 2025NextGen was initially validated through a UK pilot project with First Bus, where the parties collaborated via a special purpose vehicle (SPV) to support the procurement and operation of electrification assets under a Battery-as-a-Service model. This expanded MoU extends NextGen beyond battery-focused structures, enabling broader and more scalable deployment across additional markets outside the UK and across a wider range of asset classes. These include emobility assets such as electric vehicles and charging infrastructure, associated energy management systems, and potentially extending to energy hubs supporting industrial assets, power grids and data centers.Hitachi and MUFG Bank will also develop and scale SPV structures to finance decarbonized mobility assets for fleet and transport operators. This approach removes capital constraints and accelerates implementation, enabling operators to focus on their core transport services. From Hitachi’s side, the initiative is led by its Strategic SIB Business Unit, bringing together expertise from across Hitachi including Hitachi Energy, as ‘One Hitachi’. Hitachi will also provide managed services for asset performance and lifecycle optimization, supported by data-driven solutions from Hitachi ZeroCarbon. Through this initiative, Hitachi aims to further advance and streamline mobility and charging infrastructure operations by expanding HMAX by Hitachi, a suite of next-generation solutions that embodies Lumada 3.0, differentiated by deep domain knowledge and AI.Electrifying commercial transport at pace will require an unprecedented deployment of vehicles, charging and energy infrastructure - alongside innovative financing models to support it. Global investment in electrified transport reached around US$750 billion in 2024, making it the largest segment of the energy transition worldwide*3 - yet many fleet operators face limited access to capital and the operational complexity of transitioning at scale. Against this backdrop, Hitachi and MUFG Bank aim to expand NextGen as a repeatable model to accelerate implementation by combining structured asset financing with managed services and data-driven optimization.*3 Sources: BloombergNEF’s Energy transition Investment Trends 2025In demonstration of the expanded pipeline, Hitachi ZeroCarbon and MUFG Bank have also entered into an MoU with Boreal Norge AS and its subsidiary Boreal Buss AS, one of Norway’s primary transport operators, providing transport services across several counties and employing around 3,000 employees across its fleet, which includes over 850 buses and 35 ferries. The parties will explore how they can support Boreal’s transition planning, de-risk operations, optimize services and strengthen competitiveness as concessions evolve.Jun Taniguchi, Senior Vice President and Executive Officer, CEO of Strategic SIB Business Unit, at Hitachi, Ltd. said:“We are delighted to advance this partnership which combines Hitachi’s deep expertise in social infrastructure and digital technologies with MUFG Bank, Ltd.’s financial strength to accelerate the transition to a decarbonized society. By improving the performance of assets such as batteries and charging infrastructure through Hitachi’s digital services led by HMAX, we can truly help customers optimize the total cost of ownership. This partnership embodies our One Hitachi approach, leveraging our diverse capabilities across the Group to support our customers in achieving their net-zero ambitions.”Masakazu Osawa, Senior Managing Executive Officer Chief Executive, Japanese Corporate & Investment Banking Business Unit of MUFG Bank, Ltd., said:“Building on MUFG’s Business Co‑Creation and Investment approach, this collaboration with Hitachi aims to create value through strategic partnerships that improve society and the environment. For the global EV market, our focus is not only on strengthening Hitachi’s leading position in Battery as a Service, but also on fostering a holistic value chain — including second‑ life battery markets — that supports the acceleration of electric mobility and the achievement of 2050 net‑zero targets. Together with our partners, we are committed to co‑creating sustainable businesses that become a driving force for progress worldwide.”Nikolai Knudsmoen Utheim, Group CEO, Boreal Norge AS said:“Our priority has always been to deliver first-class transport services to our customers, whether that’s on the road, rail or over water. In exploring how we can unlock the power of electrified fleets, we can not only deliver more sustainable operations, but upgrade our infrastructure and thread technology across our entire business model for more efficient, smart transport and energy management.”About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About MUFGMitsubishi UFJ Financial Group, Inc. (MUFG) is one of the world’s leading financial groups. Headquartered in Tokyo and with over 360 years of history, MUFG has a global network with approximately 2,000 locations in more than 40 countries. The Group has about 150,000 employees and offers services including commercial banking, trust banking, securities, credit cards, consumer finance, asset management, and leasing. The Group aims to “be the world’s most trusted financial group” through close collaboration among our operating companies and flexibly respond to all of the financial needs of our customers, serving society, and fostering shared and sustainable growth for a better world. MUFG’s shares trade on the Tokyo, Nagoya, and New York stock exchanges. For more information, visit https://www.mufg.jp/english.About BorealBoreal is a leading mobility provider, operating buses, fast ferries, passenger ferries and trams in Norway and Sweden. We remain firmly committed to our societal mission of encouraging more people to travel collectively. At the same time, we are more than public transport. As the only company operating buses, ferries, fast ferries, trams and tourism services, we deliver integrated mobility solutions and travel experiences. Although Boreal is a young company in name, its heritage extends back more than 150 years. The company has around 3,000 employees and is headquartered in Stavanger, Norway. Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the European Medicines Agency (EMA) has validated the Marketing Authorisation Application (MAA) for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The filing will follow a standard review timeline.Taletrectinib (marketed as IBTROZI® in the U.S. and Japan) is a highly selective, next-generation oral treatment for patients living with advanced ROS1+ NSCLC.1 In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries* outside the U.S., China and Japan to extend the global reach of taletrectinib. Following this filing to the EMA, additional filings are planned for the U.K., Canada and other regions included in Eisai’s licensed territories.Across Europe, nearly 400,000 people are diagnosed with lung cancer each year with NSCLC accounting for 80% of cases.2,3 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5“The validation of the MAA is a significant moment for patients in Europe with ROS1+ NSCLC,” said Terushige Iike, Chief Business Officer of Eisai Co., Ltd. “With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care therapy for the thousands of patients living with this aggressive disease in Europe. We look forward to working closely with the EMA during the review process with the goal of making this treatment available to appropriate patients who urgently need targeted options.”The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally.6,7 Results from a pooled analysis of the TRUST clinical program were published in the Journal of Clinical Oncology in April 20258, and Nuvation Bio anticipates near-term disclosure of updated data reflecting even longer patient follow-up, further building on the depth and durability of responses observed to date. Additionally, given the comprehensive nature of the taletrectinib clinical dataset and based on favorable feedback received at a pre-submission meeting with the CHMP Rapporteur and Co-Rapporteur, the accepted MAA will be considered to support full approval.“Having seen the meaningful impact taletrectinib has already made for patients with ROS1+ NSCLC in the U.S., China and Japan, we are thrilled to partner with Eisai and have an accepted MAA for review in Europe,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “This accepted filing represents an important milestone in our global development strategy and brings us one step closer to delivering this highly selective, next-generation oral therapy to more patients who need it in Europe and around the world.”In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®.* Eisai’s licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and IndiaAbout ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer.9 It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease.4,5 About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain.10 The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.10,11About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com. 1About the TRUST Clinical ProgramThe TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 138 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs.6,7About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe.About Nuvation BioNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).U.S. IndicationIBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ nonsmall cell lung cancer (NSCLC).IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)1WARNINGS AND PRECAUTIONSHepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.ADVERSE REACTIONSAmong patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).DRUG INTERACTIONSStrong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI. OTHER CONSIDERATIONSPregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation. Please see accompanying full U.S. Prescribing Information.(1) Nuvation Bio Inc. IBTROZI (taletrectinib) US prescribing information. Available at: https://ibtrozipi.com/IBTROZI_taletrectinib-prescribing-information.pdf. Last accessed: March 2026(2) Wood R, Taylor-Stokes G. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage. Available here. Last accessed: March 2026(3) European Lung Foundation. Lung cancer. Available here. Last accessed: March 2026(4) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(5) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131. doi:10.1056/NEJMoa2302299. (6) ClinicalTrials.gov. A Study of AB-106 in Advanced NSCLC With ROS1 Fusion (NCT04395677). Available at: https://clinicaltrials.gov/study/NCT04395677 . Last accessed: March 2026(7) ClinicalTrials.gov. A single-arm Phase 2 study of taletrectinib in advanced ROS1-positive NSCLC (NCT04919811). Available at: https://clinicaltrials.gov/study/NCT04919811 . Last accessed: March 2026(8) Pérol M, A., et al. Taletrectinib in ROS1-positive non-small cell lung cancer: TRUST. Journal of Clinical Oncology, 43(16), 1920–1929. https://doi.org/10.1200/JCO-25-00275(9) Global Data. Diagnosed incident cases of non-small cell lung cancer across 8MM to reach 1.46 million in 2032, forecasts GlobalData. Available here. Last accessed: March 2026(10) Patil T, Smith DE, Bunn PA Jr, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol. 2018;13(11):1717-1726. doi:10.1016/j.jtho.2018.07.012.(11) Drilon A, Camidge DR, Lin JJ, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118-131.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Nuvation Bio Inc.Kaitlyn Nealymedia@nuvationbio.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Nuvation Bio Inc.JR DeVitair@nuvationbio.comForward-Looking Statements of Nuvation Bio Inc.Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding taletrectinib’s therapeutic potential and the urgent need for new therapeutic options for patients with advanced ROS1+ NSCLC in Europe, our expectations that the MAA filing for taletrectinib will follow a standard review with a decision in 1H 2027 and be considered for full approval, plans for additional filings for the U.K., Canada and other regions included in Eisai’s licensed territories, and expectations for near-term disclosure of updated data. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-K filed with the SEC on March 2, 2026 under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

The Frst New Leo Liner "L00 Series"TOKYO, Mar 27, 2026 - (JCN Newswire) - Mitsubishi Heavy Industries, Ltd. (MHI) has completed delivery of the first trainsets L00 Series ("Leo-kei") trains (4 cars per trainset, total 12 cars) ordered by Seibu Railway Co., Ltd. for its Yamaguchi Line, an automated guideway transit (AGT) system. Commercial operation of the first train began on March 27th. That same day, Seibu Railway held a commemorative ceremony for the start of commercial operation, attended by Tokorozawa City Mayor Masatoshi Onozuka and Higashimurayama City Mayor Takashi Watanabe.The new L00 Series are being manufactured at MHI's Mihara Machinery Works in Hiroshima Prefecture, and are scheduled to be delivered sequentially by FY2027. The seating arrangement has been changed from the bench seats used in the existing 8500 Series vehicles to longitudinal seats to increase transport capacity to BELLUNA DOME baseball stadium and Seibuen Amusement Park. To meet diverse passenger needs, wheelchair spaces, children's seats, and in-car information displays have been installed to enhance convenience.In addition, the new trains incorporate many unique specifications designed by MHI especially for AGT system vehicles, including aluminum bodyshells, the MHI bogie,(1), a ceiling duct air conditioning system,(2) and A-MVCS (Advanced Mitsubishi Vehicle Control System). The A-MVCS in particular, in addition to the vehicle control function, has monitoring and commissioning functions for each piece of on-board equipment, allowing it to flexibly meet the needs of railway operators.Further, a large glass window has been installed in the partition wall between the driver's cab and the children's seat, allowing children to enjoy the view from the front window and driver's seat, enhancing the sense of excitement for passengers.This AGT system utilizes rubber tires for a smooth ride and low noise. In addition, as a type of clean mobility with low CO2 emissions, the system has a reduced environmental impact, supporting the realization of a decarbonized and energy-efficient world. The adoption of vehicles that combine excellent design and environmental performance also enhances the impression of the surrounding facilities.Going forward, MHI Group will continue to strive for technological innovation, and through services that safely and comfortably transport people and goods, contribute to the development of public transport that supports the lives of people around the world.(1) A bogie developed by MHI for AGT systems. It is compatible with general rubber tire operation for AGTs.(2) A system that directs air through ducts behind the ceiling to provide air conditioning.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

KAWASAKI, Japan, Mar 27, 2026 - (JCN Newswire) - Fujitsu today announced the development of a world-leading, high-sensitivity and high-resolution infrared sensor to expand monitoring capabilities in the defense and disaster prevention fields. This sensor is a Type-II superlattice (T2SL) infrared sensor with over 1 million pixels, capable of detecting both mid-wavelength infrared (MWIR) and long-wavelength infrared (LWIR) light. Its high-sensitivity allows it to clearly capture minute thermal differences of 0.05°C or less, enabling high-precision monitoring day and night. This over 1-megapixel dual-band T2SL infrared sensor is the first of its kind in the world.The newly developed technology boasts dramatically enhanced detection and identification performance, with applications spanning a wide range of fields. For example, when applied to optical sensor systems mounted on satellites or aircraft, it can contribute to the creation of new value across diverse areas, including early assessment of disaster situations and environmental monitoring.Integrating this sensor into monitoring devices for defense and disaster prevention enables accurate detection of thermal changes, such as identifying precursors to human activity or object movement, locating people during disasters, detecting early forest fires, and monitoring tsunamis. This contributes to improving information gathering capabilities and strengthening defense and disaster prevention. Additionally, by visualizing thermal distribution and changes over time with exceptional precision, the sensor is anticipated to play a vital role in tackling societal issues like infrastructure inspection and problems with analytical equipment, while also driving progress in scientific research.This technology was developed under contract as part of the "PROTOTYPE OF WIDE BAND AND HIGH RESPONSIVITY PHOTO-DETECTORS" from Acquisition Technology & Logistics Agency (ATLA), Japan Ministry of Defense, to which Fujitsu has completed delivery of the prototype sensor.Starting in fiscal year 2026, Fujitsu plans to leverage the manufacturing technology of this sensor to develop new products and market them for use in monitoring cameras.BackgroundIn the security sector, which underpins a safe and secure society, there is a demand for advanced sensing technologies that can detect various threats early and accurately capture their precursors. However, with the diversification of monitoring scenarios and the increasing complexity of targets, there is a need for even higher resolution sensors and improved identification capabilities through simultaneous detection of multiple wavelengths. The ATLA initiated a research prototype project to establish technology that enables target detection and identification over longer distances and wider areas than existing systems. Fujitsu, which has developed and mass-produced high-sensitivity infrared sensors, was awarded this project and has now successfully completed its development.Overview of the developed sensorInfrared sensors capture infrared radiation spontaneously emitted by objects with heat, visualizing their surface temperature distribution. Fujitsu has leveraged the characteristics of T2SL, a compound semiconductor with a superlattice structure that allows for material property control, to develop a unique dual-band sensor. The superlattice structure, where different semiconductor materials are layered at the nanometer (one billionth of a meter) level, offers high sensitivity, as well as excellent control over detection wavelengths and manufacturability. By selecting a combination of semiconductor materials with a large energy offset in their band structure (i.e., Type-II Superlattice, T2SL), it is possible to detect infrared light, which has lower energy than visible light.This sensor can detect MWIR and LWIR wavelength bands, with high-sensitivity capable of detecting temperature differences of 0.05°C or less. By simultaneously detecting two wavelengths with a single pixel, it can accurately detect and identify targets that would otherwise be obscured by background noise during detection with single-wavelength sensors. Furthermore, by advancing miniaturization of elements through the development of manufacturing processes and mounting technologies suitable for delicate T2SL materials, Fujitsu has achieved high-resolution with over 1 million pixels, enabling the capture of more distant targets.This infrared sensor, simultaneously achieving high-sensitivity, high-resolution, and dual-band detection, is suitable for monitoring applications in defense, disaster prevention, and other fields requiring high discrimination performance.Furthermore, this world-first technology from Fujitsu will drive further advancements in the sensitivity, multi-band and high-resolution capabilities of conventional infrared sensors, enabling a diverse range of product developments.Figure: Dual-band T2SL infrared sensor and example imagesAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

TOKYO, Mar 26, 2026 - (JCN Newswire) - Sharp Corporation has developed long-range video monitoring technology which uses AI to analyze and record video streamed from locations 5 to 10 km away. This technology was developed in collaboration with Harada Laboratory at Kyoto University (hereinafter "Kyoto University"), Watanabe Laboratory at Waseda University (hereinafter "Waseda University"), and Oita Asahi Broadcasting Co., Ltd. (hereinafter "OAB"), as part of the Ultra-Coverage Beyond 5G Wireless and Video Coding through Japan–US–Australia R&D Collaboration project (*1) commissioned by the National Institute of Information and Communications Technology (NICT), Japan.Video analysis of grazing cattle during a field test.The video classifies difference in cattle behavior with green squares (standing) and yellow squares (feeding).Comparing the current footage (left) with the immediately preceding (40 seconds prior) footage (right), environmental changes are displayed at the top of the screen.This technology consists of long-range video transmission technology developed by Kyoto University, which enables the long-range 4K video transmission using a wireless transmission method based on very high frequency waves (VHF band), and Sharp's Dynamic Video Monitoring Technology, which recognizes the behavior of subjects in real-time without pre-training. Compared to conventional technologies, this new technology requires less preparation time for AI video analysis. In the future, this technology is expected to be utilized in a wide range of applications, including hazard detection and remote monitoring of disaster sites and evacuation shelters.To verify the effectiveness of this technology, Sharp conducted field tests in and outside Japan from March 2025 to January 2026 and demonstrated its applicability across various fields. In Japan, tests involving the monitoring of animal behavior at zoos and aquariums, as well as the streaming of live video from ships at sea were carried out. Overseas, a field test to monitor grazing cattle in remote areas has been conducted with Australia's national science agency, the Commonwealth Scientific and Industrial Research Organisation (CSIRO).To further advance the wireless communication and video compression technologies used in the long-range video monitoring technology, Sharp is submitting proposals at international standardization conferences for wireless communication and video compression, aiming for adoption in Beyond 5G, the next-generation communication standard, and Beyond VVC, the next-generation video compression standard, both to be formulated as international standards. Furthermore, Sharp is committed to supporting digital transformation through long-range wireless communication and AI technologies, aiming to apply these solutions not only to animals and ships—as demonstrated in this proof-of-concept—but also to a wide range of fields, including transportation infrastructure and disaster response.1. 4K video transmission over long distances (5 to 10 km) by long-range video transmission technology which utilizes the VHF band2. Dynamic Video Monitoring Technology (an AI technology) identifies subjects without pre-training and records changes in situations and behavior, applicable to various video analysis tasks with a shorter preparation period3. Effectiveness confirmed through field tests in and outside Japan*1 Grant No. 05101■ Key Features1. 4K video transmission over long distances (5 to 10 km) by long-range video transmission technology which utilizes the VHF bandWireless technologies used in mobile phones and other devices create coverage areas by densely deploying base stations at intervals ranging from several hundred meters to several kilometers, and transmit data between communication devices via these base stations. In contrast, the newly developed long-range video transmission technology utilizes VHF band wireless technology (*2) announced by Kyoto University, along with video compression and transmission technology. This enables the direct video data transmission between communication devices located 5 to 10 km (*3) apart, making it possible to transmit 4K video in locations where it is difficult to install base stations, such as remote islands, or within vast areas like ranches. Furthermore, since the new technology supports video transmission specification changes such as resolution and bit rate, the data transmission volume can be adjusted to suit the installation environment and intended use.Transmission range in a field test conducted in January 2026*2 For more information on this technology, please refer to the Kyoto University press release (https://www.dco.cce.i.kyoto-u.ac.jp/ja/PL/PL_2025_06.html) (in Japanese).*3 Transmission range will vary depending on the communication environment and video content.2. Dynamic Video Monitoring Technology (an AI technology) identifies subjects without pre-training and records changes in situations and behavior, applicable to various video analysis tasks with a shorter preparation periodIn video analysis, conventional AI technologies required preparatory work—such as labeling training data with information on the type, behavior, and location of subjects such as animals—as well as pre-training of the AI, which made it time-consuming to start using the system. In contrast, Dynamic Video Monitoring Technology can be activated in a shorter preparation time by applying prompts (instructions for the desired actions) along with preprocessing (*4) and postprocessing (*5) to AI which handles images and languages.*4 The processing of data to enable the AI to reason efficiently.*5 The process of converting data output by the AI into a format that is easy for users to understand and utilize.Furthermore, by combining the Dynamic Prompt Technology (*6) developed in joint with this technology, the AI automatically generates prompts based on the video content. Voice narration and quizzes based on the analysis results can be automatically produced.The AI generates narration (text at the bottom of the screen) based on the video*6 A technology which automatically generates instructions for the AI based on inputted video and context.3. Effectiveness confirmed through field tests in and outside Japan.From March 2025 to January 2026, Sharp conducted field tests in and outside Japan for various applications to confirm, its effectiveness. PeriodLocationsSubjects of analysisTest details1March 2025・Takasakiyama Natural Zoological Garden(Oita City, Oita Prefecture)・Nishi-Oita Hover Terminal(Oita City, Oita Prefecture)・Monkeys in a zoo・Footage from operating ships・Counting the animals, generating of voice narration・Long-range (approx. 5 km) video transmission to remote locations・Long-range video transmission from moving objects (ships)・Analysis of conditions within Beppu Bay as observed from the ship, voice narration generation2October 2025・CSIRO Armidale Research Farm(New South Wales, Australia)・Grazing cattle・Classification of individual animal behaviors・Recording of temporal changes3January 2026・Umitamago Oita Marine Palace Aquarium(Oita City, Oita Prefecture)・OAB head office(Oita City, Oita Prefecture)・Dolphin show・Facility beach・Long-range (approx. 6 km) 4K video transmission・Full HD video transmission for AI analysis at 1/10 the standard bit rate (approx. 300 kbps)・Analysis of the dolphin show・Generation of audio narration and quizzesAbout SharpFor more than 110 years, Sharp Corporation has been developing pioneering, world‑first and industry-first products and technologies primarily in electronics. Based on its business creed "Sincerity and Creativity", the company has established its corporate slogan "In step with your future." and aims to create New Cultures through innovative products and services in every aspect of how people live and work. Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

TOKYO, Mar 26, 2026 - (JCN Newswire) - Oki Electric Industry Co., Ltd. (TSE:6703, “OKI”), Hitachi, Ltd. (TSE:6501, "Hitachi"), and Hitachi Channel Solutions, Corp. (“Hitachi Channel Solutions”), today announced that we have agreed to enter into an agreement (“Integration Agreement”) regarding the business integration of their automated equipment businesses, including ATMs (“Business Integration”), as well as a shareholders’ agreement regarding the joint venture company established for this Business Integration (“Joint Venture Company”).Pursuant to the Integration Agreement, OKI will transfer its business responsible for the development and production of automated equipment, including ATMs, to Hitachi Channel Solutions - a wholly-owned subsidiary of Hitachi - through the Absorption-type Split. Subsequently, OKI will acquire a portion of Hitachi Channel Solutions’ shares, thereby establishing it as a joint venture. The planned ownership ratio of the Joint Venture Company will be 60% for OKI and 40% for Hitachi.Through this Business Integration, we will combine the business foundations - from development to manufacturing - that OKI and Hitachi Channel Solutions have cultivated globally over many years and establish a comprehensive service structure for terminals and branch channels targeting the financial, retail, and transportation markets. We will provide various hardware devices of automated equipment, including ATMs, which are essential social infrastructure, in a more continuous and stable manner. At the same time, we will further enhance our solutions and services that pursue added value for customers and expand our channel business based on additional customer touchpoints. With regard to the sales business for ATM-related equipment and services, we will maintain the existing framework under which OKI, Hitachi, and their respective sales subsidiaries will continue sales activities within their respective companies, as before.Going forward, following approval from the Japan Fair Trade Commission and other relevant authorities, we aim to start operations as the Joint Venture Company from October 1, 2026.Background and ObjectivesAgainst the backdrop of social structural changes such as the spread of cashless payments and the aging population, financial institutions are reevaluating the role of ATMs and branches, while the shift toward contactless operations is accelerating. Consequently, the role of ATMs is undergoing a significant transformation - moving beyond traditional cash transactions to include cardless transactions linked with QR code payments and the payment of various public utility bills - and the industry is entering a period of transformation that demands more advanced ATM functionality.Since developing the first cash-recycling ATM in 1982, OKI has expanded its automated equipment business across a wide range of sectors, including finance, retail, and transportation, contributing to the streamlining of operations involving cash and documents, as well as the improvement of services. Leveraging the strength of the OKI Group’s integrated value chain – from design and development, and manufacturing to installation and construction, maintenance and fully-outsourced ATM operation and monitoring - OKI provides high-value-added, one-stop solutions. In September 2025, OKI approximately doubled production capacity at its overseas manufacturing base, OKI VIET NAM CO., LTD., thereby strengthening OKI’s stable supply system.Hitachi and Hitachi Channel Solutions have been working to enhance services in physical settings, such as ATMs, while leveraging Hitachi Channel Solutions’ technological and development capabilities to support initiatives aimed at branch reform and digital transformation (DX), including the creation of new customer touchpoints such as “contactless” and “self-service” solutions for financial institutions. Furthermore, by utilizing the core technologies cultivated through their ATM business, Hitachi and Hitachi Channel Solutions have expanded their ATM operations globally and expanded their product and service offerings into new fields outside the financial sector.Amid this period of market transformation, the three companies agreed that combining the strengths of OKI and Hitachi Channel Solutions is essential for our customers and society. We have agreed to establish a joint venture with the aim of fulfilling our social responsibility to ensure the continuous and stable supply of ATMs - which remain a vital social infrastructure - while aiming for a shared strategic goal of growth in the global market. Furthermore, in the future, we aim to link the various data obtained from the products and service layers provided by the Joint Venture Company with Hitachi’s Lumada business. Through AI-driven analysis and utilization, we aim to support our customers - including financial institutions - in transforming their operations and creating new services, thereby jointly creating even greater customer value.About the Joint Venture CompanyThe establishment of the Joint Venture Company aims to respond to changes in the environment surrounding automated equipment, including ATMs, and to achieve sustainable business growth both in Japan and overseas. By combining OKI’s and Hitachi Channel Solutions’ expertise in solving on-site challenges, product development technologies, and manufacturing infrastructure, the Joint Venture Company will be able to create high-value-added, highly reliable products. Furthermore, by incorporating an operational framework that includes maintenance and monitoring, the Joint Venture Company will further enhance solutions and services designed to deliver added value to customers.Going forward, the Joint Venture Company plans to provide one-stop services ranging from automated equipment, such as ATMs, to related services.In Japan, the Joint Venture Company will widely provide the high-value-added products and services created to financial institutions, the retail and transportation industries, and customers in new sectors across Japan.Globally, the Joint Venture Company will promote the expansion of its world-class products and solution businesses as the core of its growth strategy. The Joint Venture Company aims to achieve high growth and strengthen its competitiveness in the global market by expanding its footprint into growth markets centered on ASEAN, as well as India and neighboring countries, North America, and MEA (Middle East and Africa), while swiftly responding to the increasingly advanced needs for ATMs, automation, and efficiency in each country.About Oki Electric Industry Co., Ltd.Founded in 1881, OKI is Japan's leading information and telecommunication manufacturer. Headquartered in Tokyo, Japan, OKI provides top quality products, technologies, and solutions to customers through its Public Solutions, Enterprise Solutions, Component Products, and Electronics Manufacturing Services businesses. Its various business divisions function synergistically to bring to market exciting new products and technologies that meet a wide range of customer needs in various sectors. Visit us at https://www.oki.com/global/.About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com.About Hitachi Channel Solutions, Corp.Hitachi Channel Solutions is committed to realizing a sustainable society under its vision: “Shaping a sustainable future by connecting the real and the digital, people and society with technology and trust.” As a pioneer in ATMs and other financial automation solutions, the company has provided products and services in more than 100 countries and regions, working to improve operational efficiency and service quality for financial institutions. In addition to the financial, retail, public, and transportation sectors, Hitachi Channel Solutions is expanding its business into new fields such as security and healthcare through automation and robotic solutions that leverage its mechatronics technologies. Visit us at www.hitachi-ch.com. Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - March 26, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa") is pleased to announce that it has received a large dataset of historic drill hole information from the Congress Gold Mine Project in Yavapai County, Arizona, USA. Comprehensive desktop technical studies integrating this data with the Company's own 2022 drilling campaign have resulted in the identification and delineation of three distinct priority exploration zones that will form the basis of the 2026 field and drilling program.HIGHLIGHTSReceipt of a large historic drill hole database greatly expanding the geological model for the Congress Gold Mine Project3D modelling of over 100 historic and recent drill holes confirms strong structural integrity and continuity of the gold-bearing vein systemsThree distinct exploration zones classified: Echo Bay Exploration Zone (~750m x 1,000m), Malartic Exploration Zone (~450m x 1,150m), and New Congress Niagara Exploration Zone (~800m x 1,000m)Echo Bay Exploration Zone designated highest priority target based on historic drill density and potential for expanded mineralization envelopeHistoric drill intercepts include highlights such as 1.2m @ 43.88 g/t Au, 2.0m @ 21.88 g/t Au, 3.3m @ 27.13 g/t Au, and 11.4m @ 4.81 g/t Au within the Echo Bay ZoneCongress Gold Mine Project is fully permitted with excellent road access and proximity to an experienced regional labor forceCompany geologists and field personnel are being mobilized for initial site preparation and drill program setupHISTORIC DRILL DATABASE COMPILATIONCasa Minerals is pleased to announce the receipt of a comprehensive dataset of historic drill hole collars, surveys, and assay records from the Congress Gold Mine Project. This data was compiled from exploration programs conducted by previous operators -- most notably Echo Bay Mines Ltd. -- during the 1980s through the early 1990s. The database encompasses a significant number of drill holes distributed across the project area, substantially expanding the known geological framework of the property.Historic exploration at the Congress Gold Mine was conducted during a period when gold market conditions were materially lower than today's environment, which directly influenced the selection criteria and cut-off grades used by previous operators. Consequently, the historic programs focused predominantly on higher-grade gold intersections, and many lower-grade vein intercepts that may be economically significant at current gold prices were not assigned the same level of analytical priority. Casa believes this creates a meaningful opportunity to reinterpret the mineralization system with a lower economic threshold, logically expanding the dimensions of the mineralization envelope that will be targeted in the forthcoming drilling season.Important Disclosure: The historic drill hole results referenced in this news release were collected and reported by previous operators under practices that predate current NI 43-101 standards. These results are disclosed solely for contextual and geological interpretation purposes. They have not been verified by a current Qualified Person, do not conform to NI 43-101, and are not classified as current mineral resources or mineral reserves. A Qualified Person has not done sufficient work to classify the historic results as current mineral resources or mineral reserves, and Casa is not treating them as such.THREE-DIMENSIONAL MODELLING AND VEIN SYSTEM VALIDATIONDesktop technical studies have included rigorous 3D modelling of all available drill hole data using industry-standard geological modelling software. The resulting three-dimensional representation of the drill hole database, illustrated in Figure A below, demonstrates the remarkable density of historic drill coverage across the project and confirms the structural coherence and continuity of the principal gold-bearing vein systems.The 3D model was constructed using NAD83 / UTM Zone 12N coordinates and captures drill holes ranging from surface to depths approaching 600 metres below ground elevation. The model reveals that:The dominant vein systems exhibit strong northeast-southwest structural orientation, consistent with the principal fault architecture identified on surfaceThe alignment and attitude of vein structures intercepted in the Company's 2022 confirmatory drilling campaign correlate with high fidelity to those projected from the historic drill hole database, validating the overall geological modelThe 2022 drilling campaign identified additional vein structures not captured in the historic database, indicating that the current geological model is likely incomplete and that the total mineralized footprint may be materially larger than previously understoodIncorporating lower-grade vein intercepts -- previously deprioritized by historic operators under lower gold price conditions -- into the mineralization envelope substantially increases the aggregate target volume for future drillingFigure A: Four-panel 3D presentation of historic and recent drill hole collars and traces, Congress Gold Mine Project. Views from west (upper left), east (upper right), oblique (lower left), and plan (lower right). Coordinate system: NAD83 / UTM Zone 12N. The high density of drill traces illustrates the extensive historic exploration coverage across the project area. Pink/magenta traces represent historic drill holes; black traces represent more recent drilling. Purple lines denote projected vein orientations.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_001full.jpgTHREE PRIORITY EXPLORATION ZONES -- 2026 PROGRAM BASISDetailed integration of the historic drill database with geological mapping, vein system mapping conducted in 2022, and structural interpretation has enabled Casa to formally classify three distinct priority exploration zones within the Congress Gold Mine Project. The classification of each zone reflects the combination of historic drill density, vein system geometry, and the nature of the gold mineralization documented to date. Figures 1 through 4 present these zones in their regional and local contexts.Figure 1: Regional overview map of the Congress Gold Mine Project showing principal vein systems (red dashed), fault corridors (blue dashed), shaft locations (Shafts 1 through 6), historic stope outlines (yellow, 1959-1987), patented claim and BLM claim outlines, and the location of the three principal exploration zones. The project is situated in Yavapai County, Arizona.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_002full.jpgEcho Bay Exploration Zone -- Highest Priority TargetThe Echo Bay Exploration Zone, measuring approximately 750 metres by 1,000 metres, is the largest and most intensively drilled zone on the property. It encompasses the historic non-NI 43-101 resource outline that was previously defined by Echo Bay Mines and represents the core of the historic gold-producing system at Congress. The zone is bounded by the principal northeast-trending veining corridors and is cut by northwest-trending fault structures that locally displace but do not terminate the mineralized vein arrays.As illustrated in Figure 2, the Echo Bay Exploration Zone hosts a dense cluster of historic drill hole intercepts distributed across the full extent of the zone. The drill hole collars and assay intercepts depicted in the figure provide compelling evidence for broad, zone-scale gold mineralization. Notably, the higher-grade intercepts are concentrated along the principal vein corridors while lower-grade disseminated and stockwork gold is documented in the intervening ground. This spatial distribution is characteristic of orogenic gold systems and is consistent with the geological setting at Congress.Selected historic drill intercepts within the Echo Bay Exploration Zone include:1.2m @ 43.88 g/t Au -- exceptional high-grade intercept within the principal vein corridor3.3m @ 27.13 g/t Au -- high-grade intercept demonstrating vein width and continuity2.0m @ 21.88 g/t Au -- high-grade vein intercept in the central portion of the zone2.4m @ 19.03 g/t Au -- confirming strong grade continuity along strike11.4m @ 4.81 g/t Au -- broad, elevated-grade intercept indicative of wide mineralization envelopes within the vein system1.5m @ 15.28 g/t Au -- demonstrating high-grade vein core and broader lower-grade haloes2.0m @ 12.19 g/t Au and 7.3m @ 11.00 g/t Au -- further confirming grade and continuity of the principal vein arrays3.1m @ 11.19 g/t Au and 2.0m @ 15.63 g/t Au -- documented in the southwestern portion of the zone, indicating lateral continuityGiven the historic drill density, the documented grade profile, and the alignment of the 2022 confirmatory drilling with the historic vein model, the Echo Bay Exploration Zone has been assigned the highest exploration priority for the 2026 program. The Company views the zone as offering the clearest near-term pathway to NI 43-101 resource delineation.Figure 2: Detailed plan map of the Echo Bay Exploration Zone (~750m x 1,000m), Congress Gold Mine Project. Shown are historic drill hole intercepts (brown dots annotated with interval length in metres and gold grade in g/t), principal vein system traces (red dashed), fault corridors (blue dashed), historic stope outlines (yellow), shaft locations, and the historic non-NI 43-101 resource outline (red hatch). Selected intercepts include 1.2m @ 43.88 g/t Au, 3.3m @ 27.13 g/t Au, 11.4m @ 4.81 g/t Au, and 2.4m @ 19.03 g/t Au, among numerous others. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_003full.jpgMalartic Exploration ZoneThe Malartic Exploration Zone covers an area of approximately 450 metres by 1,150 metres and is situated to the south and southeast of the Echo Bay Exploration Zone. The zone is named after the "Malartic-style" stratabound and vein-hosted gold mineralization that has been documented in this area of the project. Historic shaft locations CGC-003 and CGC-004 are located within this zone, providing direct underground access for potential future development.The Malartic Exploration Zone is characterized by multiple subparallel northwest-striking vein sets that have been intercepted in a series of shallow to moderate-depth drill holes. The vein system includes documented vein widths of 27 feet, 38 feet, and 55 feet (as labelled on Figure 3), indicating substantial structural corridors capable of hosting economically significant gold mineralization.Representative historic drill intercepts within the Malartic Exploration Zone include:3.6m @ 0.74 g/t Au and 10.3m @ 1.73 g/t Au -- broad lower-grade intercepts within the principal vein corridor demonstrating wide mineralization envelopes10.36m @ 1.41 g/t Au and 8.1m @ 3.53 g/t Au -- moderate-grade intercepts confirming continuity of the vein arrays7.7 @ 3.56 g/t Au and 8.1m @ 2.53 g/t Au -- further demonstrating consistent grade within vein-hosted mineralization3.2m @ 7.72 g/t Au and 2.8m @ 9.41 g/t Au -- higher-grade intercepts at the northern margin of the zone (shared boundary with the Echo Bay Zone)The Malartic Exploration Zone is relatively underexplored compared to the Echo Bay Zone, and the relatively sparse drill coverage suggests significant upside potential for zone expansion with systematic drilling.Figure 3: Detailed plan map of the Malartic Exploration Zone (~450m x 1,150m), Congress Gold Mine Project. Shown are historic drill hole intercepts (annotated with gold values), principal vein system traces, shaft locations including CGC-003 and CGC-004, historic stope outlines, and documented vein widths of 8.2m, 11.6m, and 16.8m.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_004full.jpgNew Congress Niagara Exploration ZoneThe New Congress Niagara Exploration Zone, measuring approximately 800 metres by 1,000 metres, is the northernmost of the three classified exploration zones and is situated along a structurally distinct corridor characterized by the northwest-striking New Congress-Niagara fault system. This zone encompasses historic Shaft 1 as well as drill holes CGC-008, CGC-009, and CGC-010 from the Company's 2022 exploration program.The 2022 drilling in this zone identified four discrete veins with widths ranging from 49.5 feet to 206 feet -- a notably wide structural corridor. These widths are illustrated in Figure 4 as Vein 49.5 ft, Vein 55 ft, Vein 70.5 ft, and Vein 206 ft. The scale of these structural features highlights the potential for significant bulk-tonnage style mineralization within this zone, distinct from the higher-grade but narrower veins documented in the Echo Bay Zone.Critically, the 2022 drilling at the New Congress Niagara Zone identified several vein structures that are not represented in the historic drill database, reinforcing the Company's view that the existing geological model incompletely captures the full scope of the vein system. This structural incompleteness, combined with the relatively limited historic drill coverage of this zone, underscores its exploration potential.Figure 4: Detailed plan map of the New Congress Niagara Exploration Zone (~800m x 1,000m), Congress Gold Mine Project. Shown are drill hole locations from the 2022 exploration program (CGC-008, CGC-009, CGC-010) alongside Shaft 1, with identified vein widths of 49.5 ft, 55 ft, 70.5 ft, and 206 ft. The purple outline denotes the exploration zone boundary.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1750/290037_3e63fd76341e7b14_005full.jpgPROJECT STATUS AND 2026 FIELD PROGRAMThe Congress Gold Mine Project is fully permitted for exploration and mining activities in Yavapai County, Arizona. The property benefits from:Fully permitted status: All necessary exploration and access permits are in place, enabling rapid mobilization of field crews and drilling equipmentExcellent road access: Paved and maintained road access to the property boundary facilitates cost-effective equipment and supply logisticsExperienced regional labor force: The Yavapai County region has a well-established mining and exploration workforce with proven experience in gold exploration projects of this typeInfrastructure: Existing shaft infrastructure and historic workings provide geological reference points and potential future development opportunitiesThe Company is currently mobilizing a team of geologists and field personnel to the Congress Gold Mine Project for initial site preparation, geological review, and establishment of the field infrastructure required for the 2026 drilling program. Detailed drill program parameters, including planned hole locations, depths, and targeting rationale, will be provided in a subsequent technical news release.MANAGEMENT COMMENTARY"The receipt of this historic drill database is a genuinely significant development for Casa Minerals," stated Farshad Shirvani, President and CEO. "For the first time, we now have a comprehensive view of the full scope of historic exploration at Congress, and what we see is highly encouraging. The 3D model clearly validates our 2022 findings and demonstrates that the gold system is both continuous and larger than historic estimates suggested. With gold trading at current levels, the lower-grade vein intercepts that were historically deprioritized now become compelling exploration targets in their own right. The Echo Bay Zone, with intercepts like 1.2m @ 43.88 g/t and 11.4m @ 4.81 g/t, gives us a very strong foundation from which to build a modern NI 43-101 resource. We are mobilizing our team and look forward to reporting our first drill results from the 2026 season."QUALIFIED PERSONMr. Erik Ostensoe, P.Geo., a Director and Chief Geologist of the Company, a Qualified Person as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects, has reviewed and approved the scientific and technical disclosure in this news release.ABOUT CASA MINERALS INC.Casa Minerals Inc. is a mineral exploration company focused on gold, copper, and strategic minerals exploration in North America. The Company holds a 90% interest in the historic Congress Gold Mine in Arizona and is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project. Casa's experienced management team is committed to creating shareholder value through the discovery and development of economic mineral deposits. For more information, please visit: www.casaminerals.comON BEHALF OF THE BOARD OF DIRECTORSFarshad Shirvani, M.Sc. GeologyPresident, CEO and DirectorFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements regarding: the Company's exploration plans and programs for 2026; anticipated drilling activities at the Congress Gold Mine Project; the classification and prioritization of exploration zones; expectations regarding resource definition and the potential to advance the project to NI 43-101 compliant standards; interpretations of historic drill data and 3D geological models; mineralization potential and domain expansion; and mobilization of field personnel. Forward-looking information is based on the opinions and estimates of management at the date the information is made and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated. Such factors include, without limitation: uncertainties regarding exploration results; risks related to the accuracy and completeness of historic data; the inability to verify historic assay results; variations in mineralization and grade; the speculative nature of mineral exploration; challenges in obtaining required permits and approvals; fluctuations in commodity prices; availability of financing; changes in economic and market conditions; environmental and regulatory risks; operating hazards; and other risks inherent in the mineral exploration industry. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290037 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, Mar 26, 2026 - (JCN Newswire) - Hitachi Rail announced that it will manufacture rolling stock for a new restaurant train, Fine Dining Train “vies,” in which SEIBU RAILWAY Co.,Ltd. is participating. The train is scheduled to begin operations in March 2028, and the train name and logo design have now been finalized.Realising a premium travel experience through rolling stock manufacturingDrawing on the technologies and expertise it has cultivated through the design and manufacture of railway rolling stock, Hitachi will be responsible for manufacturing the vehicles for this train. Fine Dining Train “vies” builds upon and further develops the concept established by “ Fifty Two Seats of Happiness ,” Seibu Railway’s full - course restaurant train that has been in operation since 2016, with the aim of delivering a more refined and exclusive space and dining experience. The train will be newly designed and manufactured based on the Seibu Railway flagship limited express train “Laview,” which was manufactured by Hitachi and debuted in 2019. Hitachi will apply to this project the technical know - how it has gained through the development and manufacture of Laview, including the creation of open and spacious interiors enabled by large windows, design philosophies that harmonize with surrounding landscapes, and technologies that realize a comfortable travel environment. In addition, Hitachi’s contribution extends beyond vehicle manufacturing alone. By leveraging its expertise in control and system technologies that support safe, stable operation and passenger comfort, Hitachi will help realize a travel experience in which dining and space are integrated at a high level. Through the creation of a premium travel environment that ensures safety and comfort while supporting “ quality time shared with someone special ,” Hitachi will continue to deliver new value.Key informationTrain Name: Fine Dining Train “vies”Planned Start of Operations: March 2028Rolling Stock Manufacturer: Hitachi RailNaming Development: Toshiyuki Konishi (POOL inc.)Logo Design: Hideyuki Tanno (POOL DESIGN inc.)Naming conceptFine Dining Train “vies” “Vie” means “life” or “living” in French. The name reflects respect for nature —an important value long cherished in Japan, where food is regarded as receiving life —while expressing the desire to enrich the lives of each passenger. The plural form “vies” was chosen to represent this idea. When read in reverse, “vies” reads as “Seibu,” creating a subtle narrative connection. Together with the subtitle “Fine Dining Train,” the name expresses a special dining stage where multiple lives meet and resonate through a refined culinary experience.Logo design conceptThe organic curve of the letter “s” and the underline extending from it represent the train’s distinctive form. The word “vie,” meaning “life,” “living,” and “vitality” in French, is incorporated into the design, symbolizing both rich cuisine and the passengers themselves. Rather than speed or efficiency, the logo embodies a leisurely and indulgent experience, creating a space that gently envelops its guests. The underline extending from right to left subtly alludes to the reverse reading of “vies” as “Seibu.”Seibu Railway’s restaurant trainHitachi has supported Seibu Railway’s restaurant train initiative through close collaboration with the company, including “Fifty Two Seats of Happiness ,” which has been in operation as a full - service restaurant train since April 17, 2016, following the refurbishment of Seibu Railway’s 4000 series rolling stock. Designed by architect Kengo Kuma , the exterior and interior of the train are inspired by Chichibu , one of the region’s most prominent tourist destinations. The exterior dynamically incorporates motifs of the Arakawa River flowing through the natural landscape, while the interior features traditional Chichibu Meisen textiles and l ocally sourced Nishikawa timber . The train operates mainly on weekends and holidays between Ikebukuro / Seibu - Shinjuku and Seibu - Chichibu stations, and is scheduled to mark its 10th anniversary in April 2026 .Seibu Railway 001 series limited express train “Laview”Hitachi manufactured the Seibu Railway 001 series limited express train “Laview,” positioned as Seibu Railway’s flagship train for the future, which debuted on March 16, 2019 . The name “Laview” combines the concepts of “L” for a luxurious living -like space, “a” for arrow -like speed, and “view” for the expansive scenery visible through its large windows . The train embodies the aspiration to provide passengers with an enjoyable limited express journey that gently blends into both urban and natural landscapes.About Hitachi RailHitachi Rail is committed to driving the transition to sustainable mobility and has a clear focus on partnering with customers to rethink mobility. Its mission is to help every passenger, customer, and community enjoy the benefits of more connected, smooth , and sustainable transportation.With a turnover of more than €7 billion and 24,000 employees in more than 50 countries, Hitachi Rail is a reliable partner for the world's best transport companies. The company's presence is global, but the company is local, with success based on developing local talent and investing in people and communities. Its international expertise and experience covers every part of urban ecosystems, main lines and freight railways, from high - quality production and maintenance of rolling stock to digital signalling, payment systems and smart operations. Hitachi Rail, famous for Japan's iconic high -speed train, leverages the digital and artificial intelligence expertise of Hitachi Group companies to accelerate innovation and develop new technologies.For more information, visit the hitachirail.comAbout Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY 2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

TOKYO, Mar 26, 2026 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701) announced that its FonesVisuas Test, an innovative blood test that predicts disease risk, is being offered by Royal Healthcare (*1), a Singapore-based medical institution and group company of Sojitz Corporation that combines the latest medical expertise with the art of hospitality. Entrance of the Specialist Medical Centre Interior of the Specialist Medical CentreAccording to the World Health Organization (WHO), the global rise in lifestyle-related diseases and dementia underscores the urgency for advanced predictive diagnostics (*2). Concurrently, the Organisation for Economic Co-operation and Development (OECD) iLibrary data has identified cancer and cardiovascular diseases as leading causes of mortality worldwide (*3), amplifying the urgency for proactive health management solutions.Royal Healthcare is based in Singapore's medical hub, Novena, providing personalized, high-quality health screening services alongside customized medical experiences that prioritize efficiency and convenience for both local and international patients.The addition of the FonesVisuas Test represents a significant advancement by analyzing proteins that reflect dynamic physiological changes. From just a small blood sample, the test can predict risks of developing conditions such as dementia, heart attack, lung cancer, chronic kidney disease, and prostate cancer over the next several years.Royal Healthcare combines its services with conventional health checkups to guide individuals who are not yet ill but also not in optimal health toward lifestyle improvements. This approach aims to prevent future illness and enhance people's quality of life.Looking ahead, NEC plans to expand provision of the FonesVisuas Test internationally, particularly in the APAC region, underscoring its commitment to advancing global healthcare standards.(*1)https://royal-healthcare.com/(*2)https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases https://www.who.int/news-room/fact-sheets/detail/dementia(*3)https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2023_7a7afb35-enAbout NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.For more information, please visit https://www.nec.com, and follow us on Instagram, Facebook, YouTube, and LinkedIn. Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com

Tuas South Incineration Plant (TSIP)TOKYO, Mar 26, 2026 - (JCN Newswire) - Mitsubishi Heavy Industries Asia Pacific Pte. Ltd. (MHI-AP), a regional subsidiary of the Mitsubishi Heavy Industries (MHI) Group, has been awarded a contract from Singapore's National Environment Agency (NEA) for boiler retrofit work at the Tuas South Incineration Plant (TSIP) located in the Tuas district in western Singapore. The retrofit aims to stabilize the waste handling capacity of the stoker-type incinerator(1) and extend the facility's operational lifespan. Expected completion is scheduled for the fourth quarter of 2027. The retrofit will be undertaken by Mitsubishi Heavy Industries Environmental & Chemical Engineering Co., Ltd. (MHIEC), a part of the MHI Group.TSIP was originally designed and constructed by MHI and was completed in 2000. It has a daily processing capacity of 3,000 tons and is operated and maintained by NEA.MHIEC will be responsible for the design, construction, and operational support under this retrofit contract. In Singapore, maintaining the plant's throughput while ensuring stable operations has become a major challenge. In this retrofit project, MHIEC aims to achieve both objectives by leveraging its expertise as the original designer and constructor of the existing facility to propose the optimal scope of refurbishment, which will help to extend the plant's operational lifespan. MHIEC will incorporate design modifications for certain sections of the boiler tubes to be replaced. After completion, MHIEC will also provide ongoing support to ensure reliable plant performance.MHIEC has delivered a total of four waste-to-energy incineration facilities in Singapore since commencing operations of the Tuas Incineration Plant (TIP) in 1986. In Singapore, MHIEC is strengthening its commitment not only to the conventional areas of equipment supply, facility design, and construction, but also to facility operations & maintenance services through concession business and after-sales services including operational support.MHI Group will continue its long-standing commitment to help Singapore reach its sustainable waste management and decarbonization goals through energy recovery from waste.(1) A stoker-type incinerator is a mainstream municipal waste incineration furnace that burns waste by pushing it forward on a grate composed of heat-resistant metal bars while supplying air from below.About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world’s leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com Copyright 2026 JCN Newswire. All rights reserved. www.jcnnewswire.com